Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.
Hillerdal
Gunnar
G
Department of Lung Medicine and Allergology, Karolinska University Hospital, Solna, Stockholm, Sweden. gunnar.hillerdal@karolinska.se
Sorensen
Jens Benn
JB
Sundström
Stein
S
Vikström
Anders
A
Hjerpe
Anders
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001769:Blood / Q000187:drug effects; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004890:Erythema / Q000139:chemically induced; D005260:Female; D006801:Humans; D008081:Liposomes; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D011788:Quality of Life; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D004317:Doxorubicin